> Detailanzeige

Sauer, Sandra [Verfasser:in]; Engelhardt, Monika [Verfasser:in]; Trautmann-Grill, Karolin [Verfasser:in]; Kimmich, Christoph [Verfasser:in]; Hänel, Mathias [Verfasser:in]; Schmidt-Hieber, Martin [Verfasser:in]; Salwender, Hans [Verfasser:in]; Flossmann, Carmen [Verfasser:in]; Heckmann, Hiltrud [Verfasser:in]; Ertel, Franziska [Verfasser:in]; Friederich, Andrea [Verfasser:in]; Patel, Sachin [Verfasser:in]; Thun, Barbara [Verfasser:in]; Raab, Marc-Steffen [Verfasser:in]

Treatment pattern and outcomes of re-induction therapy prior to stem cell transplantation in patients with relapsed/refractory multiple myeloma in Germany

Literatur-
verwaltung

Zur
Merkliste

Lösche von
Merkliste

Per Whatsapp teilen

Schließen

Merkliste



Sie können Bookmarks mittels Listen verwalten, loggen Sie sich dafür bitte in Ihr SLUB Benutzerkonto ein.
  • Medientyp: E-Artikel
  • Titel: Treatment pattern and outcomes of re-induction therapy prior to stem cell transplantation in patients with relapsed/refractory multiple myeloma in Germany
  • Beteiligte: Sauer, Sandra [Verfasser:in]; Engelhardt, Monika [Verfasser:in]; Trautmann-Grill, Karolin [Verfasser:in]; Kimmich, Christoph [Verfasser:in]; Hänel, Mathias [Verfasser:in]; Schmidt-Hieber, Martin [Verfasser:in]; Salwender, Hans [Verfasser:in]; Flossmann, Carmen [Verfasser:in]; Heckmann, Hiltrud [Verfasser:in]; Ertel, Franziska [Verfasser:in]; Friederich, Andrea [Verfasser:in]; Patel, Sachin [Verfasser:in]; Thun, Barbara [Verfasser:in]; Raab, Marc-Steffen [Verfasser:in]
  • Erschienen: 14 March 2024
  • Erschienen in: Bone marrow transplantation ; 59(2024), 6, Seite 880-889
  • Sprache: Englisch
  • DOI: 10.1038/s41409-024-02208-3
  • Identifikator:
  • Schlagwörter: Cancer therapy ; Combination drug therapy
  • Entstehung:
  • Anmerkungen:
  • Beschreibung: There are limited data guiding choice of re-induction therapies for patients with relapsed/refractory multiple myeloma (RRMM) prior to stem cell transplantation (SCT). We performed a retrospective medical chart review of 171 patients with RRMM in Germany who received re-induction therapy in second line (78%; n = 134) or third line (22%; n = 37) prior to re-SCT. Index therapy was defined as first completed re-induction therapy for planned myeloablative conditioning and SCT in second/third line within the eligibility period (1/2016-12/2019). Most common pre-index first line and maintenance therapy used were bortezomib-based combinations (91%; n = 155/171) and lenalidomide (55%; n = 29/53), respectively. Median duration of index therapy line was 9 months; carfilzomib-based combinations were the most widely used in second/third line re-induction therapy (49%; n = 83/171), followed by daratumumab-based combinations (21%; n = 36/171). Overall response rates in second/third line were 87% after re-induction and 96% after SCT; median time to next treatment line after start of index therapy was 31 months; median progression-free survival (PFS) was 29 months; and median overall survival after index date was not reached. Based on these data, re-induction therapy with salvage SCT appears to be beneficial in selected patients with RRMM in clinical practice in Germany, translating into deep responses, long PFS and prolonged time to next treatment.
  • Zugangsstatus: Freier Zugang